Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673238 | 1.00 | EPHX2 (0.54) | EPHX2HTR2BHTR2AHTR2CADRA1A | |
| SCHEMBL8417817 | 0.84 | EPHX2 (0.58) | EPHX2PPARG | |
| SCHEMBL1992428 | 0.84 | EPHX2 (0.58) | EPHX2PPARG | |
| SCHEMBL25735774 | 0.82 | EPHX2 (0.54) | EPHX2PPARG | |
| SCHEMBL695243 | 0.82 | EPHX2 (0.54) | EPHX2PPARG | |
| SCHEMBL12509564 | 0.79 | EPHX2 (0.51) | EPHX2PPARG | |
| SCHEMBL14125994 | 0.77 | EPHX2 (0.60) | EPHX2PPARG | |
| SCHEMBL29822568 | 0.77 | EPHX2 (0.60) | EPHX2PPARG | |
| SCHEMBL674012 | 0.77 | CNR2 (0.41) | EPHX2 | |
| SCHEMBL4628852 | 0.77 | EPHX2 (0.46) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2024105234-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2214487-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | EPHX2 1550/4885HTR2B 3479/4885HTR2A 3889/4885 |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | EPHX2 4/4885HTR2B 1790/4885HTR2A 2553/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | EPHX2 4/4885HTR2B 1894/4885HTR2A 3379/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | EPHX2 1550/4885HTR2B 3479/4885HTR2A 3889/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | EPHX2 1203/4885HTR2B 152/4885HTR2A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.